ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
September 21, 2023 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
September 21, 2023 05:30 ET
|
Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
September 06, 2023 08:00 ET
|
Apnimed, Inc.
-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month -- Exploratory Trial on the Impact of...
APNIMED to Participate in Upcoming Investor Conferences in September
August 30, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
August 28, 2023 06:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Sleep Tech Devices Market revenue to reach USD 50 Billion by 2035, says Research Nester
August 10, 2023 07:00 ET
|
Research Nester
New York, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The global sleep tech devices market size is slated to expand at ~15% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 50...
APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
August 01, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
July 12, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
July 06, 2023 08:29 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second...
Ambulatory Polysomnography (PSG) Systems Market to Garner $570.7 Million by 2031 with 6.0% CAGR | Research Dive
June 14, 2023 09:00 ET
|
Research Dive
New York, USA, June 14, 2023 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global ambulatory polysomnography (PSG) systems market is projected to generate a revenue of...